Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease
Open Access
- 10 April 2012
- journal article
- research article
- Published by SAGE Publications in Vascular Medicine
- Vol. 17 (2) , 101-107
Abstract
Inflammation is critical for atherosclerosis development and may be a target for risk-reduction therapy. In experimental studies, activation of the inflammatory regulator, nuclear factor kappa B (NFlB), contributes to endothelial activation and reduced nitric oxide production. We treated patients with coronary artery disease with sulfasalazine, an inhibitor of NFκB, and placebo in a randomized, double-blind, crossover study design. Brachial artery flow-mediated dilation (FMD) and digital vascular function were measured at baseline and after each 6-week treatment period. Of the 53 patients enrolled in the crossover study, 32 (age 60 ± 10, 22% female) completed all the visits, with a high rate of study withdrawal due to gastrointestinal side effects. In a subset of 10 participants, we compared the effects of 4 days of sulfasalazine treatment (n = 5) to no treatment (n = 5) on NFκB-regulated gene expression in peripheral blood mononuclear cells. Tumor necrosis factor α-stimulated expression of CD69 and NFlB subunit p50 was significantly blunted after 4 days of sulfasalazine treatment but not after no treatment. However, FMD and digital vasodilator response did not significantly change from baseline with long-term sulfasalazine treatment. Short-term sulfasalazine inhibited NFlB activity; however, long-term treatment was poorly tolerated and did not improve endothelial function. Our findings suggest that sulfasalazine therapy is not the optimal anti-inflammatory treatment for reversing endothelial dysfunction in cardiovascular disease. Further studies are warranted to investigate the potential for NFlB inhibition to reduce cardiovascular risk.Keywords
This publication has 37 references indexed in Scilit:
- Nuclear Factor-κB Activation Contributes to Vascular Endothelial Dysfunction via Oxidative Stress in Overweight/Obese Middle-Aged and Older HumansCirculation, 2009
- Vascular Inflammation, Insulin Resistance, and Reduced Nitric Oxide Production Precede the Onset of Peripheral Insulin ResistanceArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Cross-Sectional Relations of Digital Vascular Function to Cardiovascular Risk Factors in the Framingham Heart StudyCirculation, 2008
- Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot studyAIDS, 2008
- Predictive Value of Reactive Hyperemia for Cardiovascular Events in Patients With Peripheral Arterial Disease Undergoing Vascular SurgeryArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Overweight and Obese Humans Demonstrate Increased Vascular Endothelial NAD(P)H Oxidase-p47 phox Expression and Evidence of Endothelial Oxidative StressCirculation, 2007
- Effects of Systemic Inflammation on Endothelium-Dependent VasodilationTrends in Cardiovascular Medicine, 2006
- Simvastatin Prevents Vascular Hyporeactivity During InflammationCirculation, 2004
- Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.Journal of Clinical Investigation, 1998
- Inhibition of NF-κB by Sodium Salicylate and AspirinScience, 1994